Avidity Biosciences has started a biomarker cohort in the Phase 1/2 FORTITUDE trial for delpacibart braxlosiran (del-brax) targeting facioscapulohumeral muscular dystrophy, with enrollment expected to finish in the first half of 2025, while pursuing accelerated approval.